Alembic Pharmaceuticals Limited Reports Q3 FY25 Financial Results and Appoints Independent Director

Vadodara, India – February 3, 2025: Alembic Pharmaceuticals Limited (BSE: 533573, NSE: APLLTD) announced its unaudited financial results for the quarter and nine months ended December 31, 2024. The company reported steady revenue growth, with consolidated revenue from operations reaching ₹1,692.74 crore for Q3 FY25, reflecting an increase from the previous quarter.

Key Financial Highlights (Consolidated)​

For the nine-month period, revenue reached ₹4,902.45 crore, an increase from ₹4,711.65 crore in the previous year. Profit before tax stood at ₹502.36 crore, up from ₹448.98 crore.

Standalone Performance​

Alembic Pharmaceuticals' standalone revenue for Q3 FY25 was ₹1,406.09 crore, lower than Q2 FY25’s ₹1,580.35 crore. Net profit dropped to ₹85.92 crore from ₹166.00 crore in the previous quarter.

Segment Performance & Key Developments​

• The company's Sikkim manufacturing facility resumed full operations in February 2024 after disruptions due to flash floods in October 2023. Insurance claims amounting to ₹83.61 crore have been received, covering property damage and lost inventories.
• Exceptional income of ₹12.87 crore was recorded in Q3 FY25 due to the final insurance claim settlement.

Financial Ratios & Debt Position​

• Debt-to-Equity Ratio: 0.20, reflecting a stable capital structure.
• Operating Margin: 16.00% for Q3 FY25.
• Net Profit Margin: 8.18%, slightly lower than Q2 FY25’s 9.31%.

Corporate Governance Update​

The Board approved the appointment of Ms. Geeta Goradia as an Independent Director for five years, effective February 3, 2025. Her appointment is subject to shareholder approval via postal ballot.

Management Commentary​

"We have navigated a challenging environment with resilience, particularly in light of the operational disruptions in Sikkim. Our financial performance reflects our strong market presence and operational efficiencies. With our full manufacturing capacity restored, we anticipate sustained growth in the coming quarters," said Chirayu Amin, Chairman and CEO of Alembic Pharmaceuticals Limited.

Outlook​

Alembic Pharmaceuticals remains focused on growth through new product launches, international expansion, and cost optimization. With its manufacturing back on track, the company expects improved profitability and revenue growth in the upcoming quarters.